Research
Mixed
Obesity is a chronic, relapsing disease driven by disruptions in homeostatic, hedonic, and cognitive systems, rather than solely a lifestyle outcome, and requires multidisciplinary management including pharmacotherapy and surgery.
Treat obesity as a chronic disease, not a lifestyle failure. For eligible patients, GLP-1 agonists like semaglutide (2.4 mg weekly) combined with lifestyle changes produce significant weight loss (approx. 15%). Manage GI side effects with slow titration. Consider surgery for BMI ≥35.
StrongSupportsHIGH confidence
Obesity is a complex, chronic, relapsing yet treatable disease that stems from the disruption in the body’s homeostatic, hedonic, and cognitive systems, as a result of an interplay between genetic, metabolic, inflammatory, vascular, environmental and behavioral, and pharmacological factors.
Why this rating
The paper is a state-of-the-art review citing multiple large-scale phase III trials (STEP, SURMOUNT) and guidelines.
Source
Onboarding obesity management in cardiovascular care: A cardiologist's guide to latest advances
François Schiele et al. · American Journal of Preventive Cardiology · 2025
narrative_reviewCited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →